Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cardiometabolic Diseases Market Grown from 2024 to 2025?

The market size for cardiometabolic diseases has experienced consistent growth in recent years. Its projected expansion will see it increase from a size of $111.64 billion in 2024 to $115.7 billion in 2025, translating into a compound annual growth rate (CAGR) of 3.6%. This growth pattern in the past period is largely due to factors such as inactive lifestyles, urban and lifestyle transformations, industrial development, consumption of processed foods, hereditary factors, and environmental influences.

What Growth Rate Is Anticipated for the Cardiometabolic Diseases Market in the Coming Years?

The market size for cardiometabolic diseases is anticipated to witness consistent expansion in the upcoming years. It is estimated to reach $137.81 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.5%. The factors contributing to this growth in the forecasted period include the prevalence of obesity, continuous aging of the population, enhancements in healthcare infrastructure, developments in genomic and precision medicine, and the impact of chronic stress and mental health. Primary trends projected in this period involve health education and awareness, corporate wellness initiatives, community health activities, a prevention-oriented approach in healthcare, and integrated care methods.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11929&type=smp

Who Are the Leading Companies in the Cardiometabolic Diseases Market?

Major companies operating in the cardiometabolic diseases market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Thermo Fisher Scientific, Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton, Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Biocrates Life Sciences AG, Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Agilent Technologies, Edwards Lifesciences, Bruker Corporation, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Cardax Inc.

What Are the Key Drivers of the Cardiometabolic Diseases Market?

The cardiometabolic disease market is projected to expand due to the rising incidence of obesity. Characterized by an excessive accumulation of body fat leading to an increase in body weight, obesity is a multifaceted condition. It directly contributes to the emergence of cardiovascular risk factors like dyslipidemia, type 2 diabetes, hypertension, and sleeping disorders. For example, as stated by the World Health Organization (WHO) – an intergovernmental body headquartered in Switzerland, in March 2022, over 1 billion people worldwide are grappling with obesity. This figure includes 340 million teenagers, 650 million adults, and 39 million children annually. The WHO anticipates that, by 2025, 167 million adults and children will experience a deterioration in their health due to being overweight or obese. Consequently, the escalating prevalence of obesity is stimulating the growth of the cardiometabolic diseases market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11929&type=smp

What Are the Key Market Segments in the Cardiometabolic Diseases Industry?

The cardiometabolic diseases market covered in this report is segmented –

1) By Type: Chronic Or Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity

2) By Treatment: ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments

3) By Dosage: Tablet, Injection

4) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration

5) By End-Users: Clinic, Hospital, Other End-Users

Subsegments:

1) By Chronic Or Congestive Heart Failure: Systolic Heart Failure, Diastolic Heart Failure

2) By Hypertension: Primary Hypertension, Secondary Hypertension

3) By Type 2 Diabetes: Insulin Resistance, Impaired Glucose Tolerance

4) By Obesity: Class I Obesity (BMI 30-34.9), Class II Obesity (BMI 35-39.9), Class III Obesity (BMI 40 And above)

What Are the Latest Trends in the Cardiometabolic Diseases Market?

A prevalent trend emerging in the cardiometabolic diseases market is the incorporation of cutting-edge technologies. Enterprises participating in the cardiometabolic diseases market are leveraging innovative technologies to maintain their market presence. Take for example, Eko Health Inc., a US enterprise specializing in digital health technologies for heart and lung diseases identification. In February 2023, they launched the Sensora cardiac disease detection platform. This platform uses artificial intelligence (AI) to accurately identify structural murmurs – an indication of valvular heart disease (VHD). Moreover, the platform’s care pathway analytics software offers key metrics and insights about the patient’s journey through the healthcare system. The digital stethoscope is utilized for recording and examining electrical impulses and heartbeats.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

What Are the Key Regional Markets in the Cardiometabolic Diseases Industry?

North America was the largest region in the cardiometabolic diseases market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11929

This Report Delivers Insight On:

1. How big is the cardiometabolic diseases market, and how is it changing globally?

2. Who are the major companies in the cardiometabolic diseases market, and how are they performing?

3. What are the key opportunities and risks in the cardiometabolic diseases market right now?

4. Which products or customer segments are growing the most in the cardiometabolic diseases market?

5. What factors are helping or slowing down the growth of the cardiometabolic diseases market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model